Sutro Biopharma Inc (NAS:STRO)
$ 3.84 0.15 (4.07%) Market Cap: 314.74 Mil Enterprise Value: -97.02 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 62/100

Sutro Biopharma Inc at Wedbush PacGrow Healthcare Conference- Panel Transcript

Aug 10, 2022 / 06:20PM GMT
Release Date Price: $6.73 (+1.97%)
David Matthew Nierengarten
Wedbush Securities Inc., Research Division - MD & Head of Healthcare of Equity Research

Thank you, everyone, for joining us here at the Wedbush PacGrow Healthcare Conference. We're going to have a panel discussion now on antibody drug technologies and maybe some more exotic chemistry and biochemistry here, too, given the flexibility of our panelists platforms.

With us today from Mersana, Sutro and CytomX, we have Anna Protopapas, CEO of Mersana; Bill Newell, CEO of Sutro; and Sean McCarthy, CEO of CytomX. Maybe we can just start with a quick intro from each of you on the highlights of your platform, just the quick 30 seconds or so on what you think is the best part of your platform and then we can go into some Q&A.

Speaking of Q&A, before we get into that, if you have a question, anybody in the audience has a question, please type it in the dialogue box that you should have beneath the screen upon which you're viewing this webcast.

So without further ado, maybe, Anna, we can start with you just, again, a quick intro and highlights of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot